Telomir Pharmaceuticals, Inc.

Three drug startups collectively raised more than $700 million in initial public offerings Thursday, a flurry of activity after a largely fallow summer in which few biotechnology companies made the jump to public markets.Cancer biotech BicaraTherapeutics secured $315 million in the third-largest IPO of the year, according to BioPharma Dive data. Autoimmune drug developer Zenas BioPharma followed with a $225 million stock sale, while MBX Biosciences, which is studying endocrine and metabolic conditions including obesity, raised $163 million.All three met projections they set the past few weeks. Bicara hiked its offering size by 25% before pricing and still sold more shares than anticipated. Zenas and MBX upsizedtheir IPOs as well.The trio of offerings is a notable occurrence this year. So far, 18 biotechs have now priced IPOs in 2024, in line with each of the prior two years but well below pre-pandemic totals. More than half currently trade below their offering price, BioPharma Dive data show.As in the past two years, lengthy dry spells have followed bursts of IPO activity. Prior to Thursday, the last time three biotechs went public in the same week was in early February, when cell therapy developer Kyverna Therapeutics, gene editing company Metagenomi and anti-aging startup Telomir Pharmaceuticals raised about $420 million over two days.By and large, the companies making it to an IPO have been later-stage, with drugs already in human testing. But even for those firms, the market remains challenging and, in recent months, there have been more buyout deals for private biotechs than IPOs. The pattern suggests young drugmakers and their backers are opting to sell, while pharmaceutical companies are finding bargains in mature startups that arent yet public.Even with the spike in private acquisitions, there is a backlog of startups that are relying on later funding rounds to stay afloat and wait for the right opportunity. Their arrival onto the market may be delayed by U.S. elections in November and uncertainty around interest rates, however.We dont anticipate a rapid recovery until the dust settles on macro uncertainties, but expect to see an uptick in companies going public in early '25, wrote Jefferies analyst Michael Yee in an investor note this summer.The IPOs Thursday may offer a glimpse of whats to come. All three secured hundreds of millions of dollars in venture investment prior to testing Wall Street, and each has drug prospects in Phase 1 testing or later.Bicara is advancing a bifunctional antibody drug for a type of head and neck cancer. Later this year or early next, it expects to begin a late-stage trial evaluating the drug alongside Merck & Co.s Keytruda in people newly diagnosed with the disease. Bicara plans to test the drug in other solid tumors, too.Meanwhile, Zenas is riding a wave of interest in immunology drugs. A dual-targeting antibody its been developing is in Phase 3 testing for an inflammatory condition called IgG4-disease and a Phase 2 study for a type of anemia. The company may also soon start mid-stage trials in multiple sclerosis and lupus. Its IPO is the fifth for an immune drug developer this year, the most since 2021, BioPharma Dive data show.MBX Biosciences specializes in metabolic disease, another area of research thats attracted increasing investment. Its lead drug is in a Phase 2 study for hypoparathyroidism. The company also has a treatment in earlier testing for complications of bariatric surgery, as well as a preclinical obesity drug.Kairos Pharma, a developer of small molecule cancer drugs, was also scheduled to price a smaller, $6 million offering Thursday. '

Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Out of respect and privacy for Dr. Chapman’s family, details of his passing will not be made available. Telomir’s Board of Directors has named Erez Aminov, currently Chairman of the Board and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), as a director, Chairman of the Board and Chief Executive Officer of Telomir. To offer support to Telomir’s new senior management, three Telomir directors have voluntarily resigned from the Telomir Board of Directors, and three individuals have been appointed as replacements. The new Telomir directors are Dr. Matthew P. Del Giudice, Mr. Ned MacPherson and Matthew Pratt Whalen, CPA. Dr. Craig Eagle and Michael Jerman, each sitting directors of Telomir, will remain on the Telomir Board of Directors. The resigning directors are Hugh McColl III, Talhia Tuck and Brad Kroenig. Dr. Craig Eagle, an independent member of Telomir’s Board of Directors, stated: “The entire Telomir community is devastated by the loss of Dr. Chapman. Not only was he a founding officer and director of Telomir, but he was a leading scientist and researcher as well as a kind and decent man. Our thoughts and thanks go out to Dr. Chapman’s family. We are also grateful to Erez for joining our company to fill these important roles as Telomir continues to progress its business.” Mr. Aminov stated, “Dr. Chapman’s passion for the potential of Telomir-1 is inspiring, and I hope to carry on with his work with that same passion. I appreciate the trust that the Telomir board has placed in me at this challenging time. I look forward to working with Telomir and moving its promising drug candidate forward.” About Telomir Pharmaceuticals, Inc. Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially promote longevity in humans and dogs through the treatment of age-related conditions. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents us with an increased chance of contracting a number of degenerative and age-related diseases. Telomir’s goal is to develop and commercialize Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the appointment of Mr. Aminov to his positions with the Company. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 and the aging process and safety of Telomir-1 . These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. For further information, please contact: Telomir Pharmaceuticalsinfo@Telomirpharma.com(813) 864-2558

TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps as a potential treatment for age-related conditions, today announced that the Company has been added as a member of the broad-market Russell 3000® and the Russell Microcap® Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® and Russell Microcap® Indexes, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. “The inclusion of Telomir in the Russell 3000® and the Russell Microcap® Indexes demonstrates the progress that we have made as a publicly-traded company since our initial public offering in February,” said Dr. Chris Chapman, Co-Founder, Chairman, CEO, President and CMO of Telomir. “Coupled with our recently announced milestones for our lead product candidate, Telomir-1, we believe that Telomir is well-positioned to achieve many of our corporate and clinical objectives in the second half of 2024 and beyond, and we remain committed developing and commercializing Telomir-1 to reverse age-related conditions.” Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of December 2023, about $10.5 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, a prominent global index provider. For more information about the Russell 3000® Index, the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website. To be added to the Telomir Pharmaceuticals email distribution list, please email telomir@kcsa.com with TELO in the subject line. About Telomir Pharmaceuticals, Inc. Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents us with an increased chance of contracting a number of degenerative and age-related diseases. Telomir’s goal is to develop and commercialize Telomir-1 (which is proposed to be dosed orally) for a broad range of age-related inflammatory conditions such as osteoarthritis. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding completion, timing and anticipated size of the initial public offering and the expected commencement of trading on the Nasdaq. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 and the aging process and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. For further information, please contact:KCSA Strategic Communications Phil Carlsontelomir@kcsa.com Telomir Pharmaceuticalsinfo@Telomirpharma.com(813) 864-2558